Evidence map›Paper›PMID 38125392›Full record

ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2022

National Influenza Annual Report, Canada, 2021-2022: A brief, late influenza epidemic.

Steven Buckrell, Myriam Ben Moussa, Tammy Bui, Abbas Rahal, Kara Schmidt, Liza Lee, Nathalie Bastien, Christina Bancej

Open access · diamondAbstract read
In one paragraph

Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Establishing Pandemic Influenza Severity Assessment (PISA) parameters and thresholds for Canada's FluWatch program.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023
    Article
  5. AMMI Canada 2023 update on influenza: Management and emerging issues.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2023
    Article
  6. National Influenza Annual Report, Canada, 2022-2023: Canada's first fall epidemic since the 2019-2020 season.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023
    Article
  7. Article
  8. Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Article
  9. National influenza mid-season report, 2022-2023: A rapid and early epidemic onset.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Steven BuckrellCentre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Myriam Ben MoussaCentre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Tammy BuiCentre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Abbas RahalCentre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Kara SchmidtCentre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Liza LeeCentre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Nathalie BastienNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.
Christina BancejCentre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Public Health Agency of Canada · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Canadian seasonal influenza circulation had been suppressed since the beginning of the coronavirus disease 2019 (COVID-19) pandemic. This suppression was reported globally and generated concern that the return of community influenza circulation could be intense and that co-circulation of influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was possible and potentially severe. Community circulation of influenza returned to Canada during the 2021-2022 influenza season. The influenza epidemic began in week 16 (mid-April 2022) and lasted only nine weeks. This epidemic was driven by influenza A(H3N2) and was exceptionally late in the season, low in intensity and short in length. Community co-circulation of influenza and SARS-CoV-2 was observed in Canada for the first time during the 2021-2022 seasonal influenza epidemic. The unusual characteristics of the 2021-2022 influenza epidemic suggest that a breadth of factors moderate transmission dynamics of the two viruses. Concerns of an intense seasonal influenza epidemic did not come to fruition during the 2021-2022 season; therefore, high influenza susceptibility remains, as does predisposition to larger influenza epidemics. Ongoing circulation of SARS-CoV-2 creates uncertainty about dynamics of future influenza epidemics, but influenza vaccination remains a key public health intervention available to protect Canadians. Public health authorities need to remain vigilant, maintain surveillance and continue to plan for both heightened seasonal influenza circulation and for the potential for endemic co-circulation of influenza and SARS-CoV-2.

Indexed as

COVID-19influenzainfluenza-like illnesspandemic preparednesssurveillance

Identifiers

PMID38125392
PMCPMC10730107
OpenAlexW4307325077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.